Article History
Received: 31 July 2019
Accepted: 3 January 2020
First Online: 16 January 2020
Compliance with ethical standards
: This research received Institutional Review Board approval from the WIRB: #20181009.
: Given the highly personal nature of the data collected in this study, respondent privacy and anonymity were of high concern. As guaranteed in the GDPR-compliant consent form that each participant signed, personal data was handled with the utmost care. In order to identify the different participants while preserving confidentiality, each respondent in the study was given a pseudonym.
: This research was supported by Bristol-Myers Squibb, a company that developed one of the four IO drugs that qualified patients for study participation. The other three drugs were made by different pharmaceutical manufacturers.
: Bristol-Myers Squibb had no role in the design, collection, analysis, or interpretation of data. The writing of the manuscript and the decision to submit the manuscript for publication were made after the research was completed and carried out by Dr. Rebekah Park, one of the research team members, and by Dr. James W. Shaw of Bristol-Myers Squibb.